- Price is above Fair Value, showing premium demand versus the model.
EDSA
NASDAQ
Week ended 07 Aug 2026
Weekly Investor Report
Edesa Biotech Inc · Healthcare · Biotechnology
Latest close
5.27 USD
3.1%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is -15.9% below the Trend Line and sits at 23.2% of its 52-week range. The latest completed week returned 3.1%, after a -24.8% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 54/100. Near-term considerations: volume confirmation is below normal; earnings are due in 1d.
Setup score
31
out of 100
Latest Close
5.27 USD
7 Aug 2026
1W Return
3.1%
latest completed week
4W Return
-24.8%
short-term follow-through
12W Return
-59.6%
quarterly tape
Trend Breadth
51.9%
27 of 52 weeks active
Volume Ratio
0.2x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Activity pressure is negative, which weakens the current setup.
- Activity pressure is weak, so confirmation is not yet broad enough.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
3.1%
Latest completed week; four-week move -24.8%.
Indicator stack
29/33
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
54/100
50 relevant articles in the latest sentiment read.
Event risk
1d
Next report is scheduled for 14 Aug 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -15.9% below the Trend Line and sits at 23.2% of its 52-week range. The latest completed week returned 3.1%, after a -24.8% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.2x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.4312-week average 0.74
12-week confirmation
Trend active10/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure3/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.43Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -24.8% over four weeks, -59.6% over 12 weeks, and 148.6% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year27
Trend breadth51.9%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-0.72Latest activity-pressure read.
Pressure change-53.2%Four-week change in activity pressure.
Leadership6.67Latest relative-leadership reading.
RS change-86.1%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 76%
Model confidence 71%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength65/100Blend of value, momentum, and quality. Underlying universe rank 36; rank 1 is best.
Value57/100Relative valuation strength. Underlying universe rank 44; rank 1 is best.
Quality55/100Profitability and accounting quality. Underlying universe rank 46; rank 1 is best.
Momentum57/100Medium-term price momentum. Underlying universe rank 44; rank 1 is best.
Growth57/100Revenue and earnings growth. Underlying universe rank 44; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 997.0x Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -15.6% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- -202.3% Gross profit retained from each unit of revenue.
- Operating margin
- -20782.3% Operating profit retained from revenue.
- Free-cash-flow margin
- -15033.8% Free cash flow generated from revenue.
- Return on invested capital
- - Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- - Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 2/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -7.3% Net share repurchases relative to market value.
- Shareholder yield
- -7.3% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 1.0x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity14 / 0
14 acquisitions and 0 disposals in the latest 180-day insider tape.
Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.News sentiment54/100
Weighted news tone is neutral across 50 relevant articles.
15 positive · 31 neutral · 4 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings1dNext report is scheduled for 14 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-74.1%Distance below the 52-week high.
13-week volatility15.6%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher11 of 2615 weeks finished lower.
Best week+196.4%Week of 6 Mar.
Worst week-31.0%Week of 29 May.
Latest week+3.1%Week of 7 Aug.
Shape of recent returns
Strong gains10
Modest gains1
Flat weeks0
Modest losses1
Sharp losses14
Recent vol15.6%13-week weekly-return volatility.
Base vol42.8%52-week weekly-return volatility.
Up/down split22/29Count of positive and negative weeks in the 52-week window.
Average skew30.7% / -11.1%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average2.6%
Trend breadth54.0%
Trend54.0%active weekly trend signals
MD77.0%positive activity pressure
RS44.0%positive relative leadership
Four-week leaders
IndustryUS Biotechnology
4-week rank- / 100
Group average0.5%
Trend breadth70.0%
Trend70.0%active weekly trend signals
MD64.0%positive activity pressure
RS62.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape37/100
Trend, activity pressure, participation, and risk combine to a 37/100 tape read.
Indicator analysis61/100Latest 12-week confirmation: trend 10/12, activity pressure 3/12, relative leadership 12/12.
Activity pressure 0.43; No reversal markers Factors58/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 85; Small Cap Core rank 49 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment54/100Weighted news tone is neutral across 50 relevant articles.
Edesa Biotech (EDSA) to Post Earnings on Monday Insiders14 / 014 acquisitions and 0 disposals in the latest 180-day insider tape.
Earnings1dNext report is scheduled for 14 Aug 2026; event risk rises as the date approaches.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 5.27 USD | 3.1% | 6.26 USD | 3.88 USD | -0.72 | 6.67 | 183.3K | Off |
| 31 Jul 2026 | 5.11 USD | -2.7% | 6.14 USD | 3.89 USD | -0.62 | 9.81 | 441.4K | Off |
| 24 Jul 2026 | 5.25 USD | -20.5% | 6.02 USD | 3.90 USD | -0.56 | 14.59 | 349.6K | On |
| 17 Jul 2026 | 6.60 USD | -5.8% | 5.89 USD | 3.90 USD | -0.49 | 43.18 | 240.3K | On |
| 10 Jul 2026 | 7.01 USD | -6.5% | 5.72 USD | 3.89 USD | -0.47 | 47.98 | 272.4K | On |
| 3 Jul 2026 | 7.50 USD | -8.4% | 5.54 USD | 3.88 USD | -0.48 | 64.03 | 382.7K | On |
| 26 Jun 2026 | 8.19 USD | 11.4% | 5.35 USD | 3.87 USD | -0.44 | 84.40 | 577.8K | On |
| 19 Jun 2026 | 7.35 USD | 26.7% | 5.14 USD | 3.86 USD | -0.31 | 61.93 | 863.1K | On |
| 12 Jun 2026 | 5.80 USD | 6.2% | 4.95 USD | 3.85 USD | -0.03 | 33.79 | 1.4M | On |
| 5 Jun 2026 | 5.46 USD | -24.4% | 4.81 USD | 3.85 USD | 0.35 | 30.69 | 1.7M | On |
| 29 May 2026 | 7.22 USD | -31.0% | 4.69 USD | 3.86 USD | 0.71 | 67.36 | 1.3M | On |
| 22 May 2026 | 10.46 USD | -19.8% | 4.51 USD | 3.85 USD | 1.00 | 154.50 | 2.5M | On |
| 15 May 2026 | 13.05 USD | -19.9% | 4.25 USD | 3.82 USD | 1.07 | 233.37 | 1.3M | On |
| 8 May 2026 | 16.30 USD | -7.3% | 3.90 USD | 3.78 USD | 1.02 | 337.12 | 2.0M | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.